首页> 美国卫生研究院文献>PLoS Medicine >No Treatment versus 24 or 60 Weeks of Antiretroviral Treatment during Primary HIV Infection: The Randomized Primo-SHM Trial

【2h】

No Treatment versus 24 or 60 Weeks of Antiretroviral Treatment during Primary HIV Infection: The Randomized Primo-SHM Trial

机译：原发性HIV感染期间无治疗与24或60周的抗逆转录病毒治疗：随机Primo-SHM试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundThe objective of this study was to assess the benefit of temporary combination antiretroviral therapy (cART) during primary HIV infection (PHI).

机译：背景本研究的目的是评估在原发性HIV感染（PHI）期间临时联合抗逆转录病毒疗法（cART）的益处。

著录项

期刊名称 PLoS Medicine
作者
Marlous L. Grijsen; Radjin Steingrover; Ferdinand W. N. M. Wit; Suzanne Jurriaans; Annelies Verbon; Kees Brinkman; Marchina E. van der Ende; Robin Soetekouw; Frank de Wolf; Joep M. A. Lange; Hanneke Schuitemaker; Jan M. Prins;
展开▼
作者单位

展开▼
年(卷),期 2012(9),3
年度 2012
页码 e1001196
总页数 12
原文格式 PDF
正文语种
中图分类基础医学;
关键词

相似文献

外文文献
中文文献
专利

1. No Treatment versus 24 or 60 Weeks of Antiretroviral Treatment during Primary HIV Infection: The Randomized Primo-SHM Trial [J] . Marlous L. Grijsen, Radjin Steingrover, Ferdinand W. N. M. Wit, PLoS Medicine . 2012,第3期

机译：原发性HIV感染期间无治疗与24或60周的抗逆转录病毒治疗：随机Primo-SHM试验
2. Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: Week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial [J] . VernazzaP., WangC., PozniakA., JAIDS: Journal of acquired immune deficiency syndromes . 2013,第2期

机译：lersivirine（UK-453,061）与efavirenz在未接受抗逆转录病毒治疗的HIV-1感染患者中的疗效和安全性：第48周的主要分析结果来自正在进行的，多中心，随机，双盲的IIb期临床研究
3. Temporary antiretroviral treatment during primary HIV-1 infection has a positive impact on health-related quality of life: Data from the Primo-SHM cohort study [J] . GrijsenM.L., KosterG.T., vanVonderenM.G.A., HIV medicine . 2012,第10期

机译：原发性HIV-1感染期间的临时抗逆转录病毒治疗对与健康相关的生活质量有积极影响：Primo-SHM队列研究的数据
4. PREVENTION OF HIV-1 INFECTION WITH EARLY ANTIRETROVIRAL THERAPY: TREATMENT AS PREVENTION-TASP [C] . ISHWAR GILADA, T. GILADA International Seminar on Nuclear War and Planetary Emergencies . 2014

机译：预防早期抗逆转录病毒治疗的HIV-1感染：治疗预防 - TASP
5. Indirect pulp treatment versus formocresol pulpotomy in human primary molars: A randomized controlled trial. [D] . Roberts, John David. 2009

机译：在人原发性磨牙中间接牙髓治疗与甲酚甲切开术：一项随机对照试验。
6. Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial [O] . Sharon Walmsley, Axel Baumgarten, Juan Berenguer, -1

机译：简要报告：Dolutegravir加上Abacavir / Lamivudine用于初治抗逆转录病毒疗法的患者的HIV-1感染：单项随机临床试验的96周和144周结果
7. No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: The randomized primo-SHM trial [O] . Grijsen F.J., Steingrover R. (Radjin), Wit F.W.N.M. (Ferdinand), 2012

机译：原发性艾滋病毒感染期间不进行治疗与进行24或60周的抗逆转录病毒治疗：随机的primo-SHM试验

No Treatment versus 24 or 60 Weeks of Antiretroviral Treatment during Primary HIV Infection: The Randomized Primo-SHM Trial

摘要

著录项

相似文献

相关主题

期刊订阅